Interaction Guide · Research summary

Can I take Curcuma Longa with Ticagrelor?

Review Curcuma Longa with Ticagrelor: possible adverse effects, preparation details, evidence limits, and sources.

Prepared by Dr. Edward M.Kim, PharmD · Clinical Director, SupplementSafety editorial team

Research summary published · Prepared · Editorial update

The short answer

The added bleeding risk from Curcuma longa with ticagrelor is uncertain. Review the exact product, dose and your bleeding history with your prescriber.

What this answer covers

Oral Curcuma longa with oral ticagrelor tablets. Exact formulation, dose and duration matter; other antiplatelet medicines and other supplement preparations are not interchangeable.

Supplement or preparation
Curcuma longa
Medication ingredient
ticagrelor

What the evidence shows

A small study of turmeric alone and with aspirin found no clinically relevant overall added platelet or coagulation effect. It did not test ticagrelor or rule out uncommon bleeding.

Consider the prescribed treatment

Ticagrelor reduces platelet activity and can cause serious bleeding. The label also warns that stopping it increases cardiovascular risk, including stent-related harm in relevant patients. Have your prescribing team review supplements and procedure plans; do not stop ticagrelor or assume that a few hours of spacing removes a possible bleeding concern.

Review the exact product

Review the preparation, dose and additional ingredients such as piperine. Food turmeric, purified curcumin and concentrated multi-ingredient extracts are different exposures. Separate product toxicity does not establish a measured bleeding, liver or GI interaction for every preparation.

Know when to get help

Seek urgent care for bleeding that will not stop, vomiting blood or black, tarry stools. Tell your prescriber about the full supplement and medicine list. Do not stop prescribed antiplatelet treatment on your own to accommodate a supplement; ask the treating team to make a plan.

Evidence and practical considerations

Side effects & toxicity

An increased bleeding rate specifically from Curcuma longa with ticagrelor has not been established.

Exact scope
Oral Curcuma longa with oral ticagrelor tablets. Exact formulation, dose and duration matter; other antiplatelet medicines and other supplement preparations are not interchangeable. with Exact ticagrelor RxCUI1116632 IN. Oral parent drug and active metabolite have antiplatelet activity; other P2Y12 drugs are not interchangeable.
Medication form and route
Oral

What remains uncertain

  • Available supplement-only and other-drug studies do not establish exact-pair clinical harm or exclude rare events. No validated preventive spacing interval.

Factors that may matter: Exact preparation and dose; Fasting versus fed dosing; Bleeding and ulcer history; Other medicines.

Research conclusion: insufficient evidence · Evidence assessment: low

Read the supporting source summaries

Source 1: Current prescribing information

dailymed.nlm.nih.gov · Source check Sep 10, 2026

Population: Prescription oral oral ticagrelor tablets users; short human pharmacology studies where described.

Significant bleeding risk; stopping treatment raises cardiovascular risk. Strong CYP3A inducers lower exposure and efficacy and should be avoided.

How this applies: Exact current product label. Exact ticagrelor RxCUI1116632 IN. Oral parent drug and active metabolite have antiplatelet activity; other P2Y12 drugs are not interchangeable.

No exact botanical bleeding rate. Rifampin exposure changes are not an effect size for St. John’s wort.

Source 2: Original clinical research

pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026

Population: Approximately 25 healthy volunteers assigned per herb.

No clinically relevant overall platelet/coagulation change or added aspirin inhibition. No significant bleeding manifestations reported.

How this applies: Indirect for oral ticagrelor tablets co-use; exact preparation and endpoint retained.

Abstract-only; small short study, preparation detail incomplete. Occasional individual platelet responses do not establish clinical bleeding; rare harm or different products not excluded.

Source 3: Medication terminology

rxnav.nlm.nih.gov · Source check Sep 10, 2026

Population: Terminology.

ticagrelor is IN.

How this applies: Exact identity.

Not clinical evidence.

Research assessment: · Open full citations ↗

Review and change history

Publication status
Published research summary
Clinical review
Not yet recorded
DateUpdate
Article prepared
Sources checked and article drafted.
Research summary published

Article revision: 2981965b5309a682

This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.

Full citations require verification. Reading this answer and the source summaries does not.

Taking other supplements or medications?

Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.

Open the interaction checker

Information, not medical advice. Do not change prescribed treatment based on this guide.